Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia
- PMID: 11972092
- DOI: 10.1097/00043426-200205000-00008
Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia
Abstract
Background: Validating published risk models in a different time and setting can be a labor-intensive process. Data in electronic format provide the potential to test the validity of risk models without labor-intensive chart reviews and data capture. The authors attempted to use readily available electronic data to find appropriate cases and to validate and refine a previously developed risk model for predicting bacteremia in children with cancer who had fever and neutropenia.
Patients and methods: By applying a largely automated case-finding algorithm to linked, electronic clinical and administrative data systems, the authors identified and acquired data regarding 157 episodes of fever and neutropenia in children with cancer admitted to a children's hospital during an 11-month period in 1997. The authors applied a previously developed and validated risk model for bacteremia to this 1997 cohort by assessing the odds ratios among risk groups. The model assigns encounters with absolute monocyte count of 100 cells or more/mm3 to a low-risk group and encounters with an absolute monocyte count of less than 100 cells/mm3 to intermediate-risk (temperature <39.0 degrees C) or high-risk (> or = 39.0 degrees C) groups. In addition, the authors explored whether the new data would have generated the same model. Univariate and multivariable analyses were performed to determine whether there were additional independent predictors of bacteremia. Recursive partitioning of admission absolute monocyte count and temperature was used to assess whether similar cutpoints would be found.
Results: There were 12 episodes of bacteremia (7.6%) among the 157 encounters. The previously developed model correctly predicted increasing rates of bacteremia in this 1997 cohort, ranging from 2.5% in the low-risk group (one episode in a child with an infected central line) to 24% in the high-risk group. The odds ratio for the high-risk versus intermediate-risk group was 4.09 (95% confidence interval 1.05-15.91), comparable to the odds ratio of 3.96 in the previously published derivation cohort (95% confidence interval 1.4-11.1). Multivariate analysis of the new data revealed no independent risk factors for bacteremia other than admission absolute monocyte count and temperature. Recursive partitioning of absolute monocyte count and temperature generated risk categories that were somewhat different from those of the original model. The new data yielded three categories: low risk (temperature < or = 39.5 degrees C and absolute monocyte count >10/mm3), intermediate risk (temperature < or = 39.5 degrees C and absolute monocyte count < or = 10/mm3), and high risk (temperature >39.5 degrees C).
Conclusions: Existing electronic data provide an efficient means for case-finding and model validation and refinement. The previously developed bacteremia model had good but not optimal predictive performance in the new data set. Admission absolute monocyte count and temperature remain significant risk factors for bacteremia. Redefining the risk categories, including a much lower cutpoint for admission absolute monocyte count, improved the model's discrimination, which suggests that predictive models need periodic updating.
Similar articles
-
Predicting the risk of bacteremia in childen with fever and neutropenia.J Clin Oncol. 1996 Mar;14(3):919-24. doi: 10.1200/JCO.1996.14.3.919. J Clin Oncol. 1996. PMID: 8622040
-
Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges.J Pediatr Hematol Oncol. 2002 May;24(4):263-8. doi: 10.1097/00043426-200205000-00009. J Pediatr Hematol Oncol. 2002. PMID: 11972093
-
Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia.Cancer. 2001 Aug 15;92(4):909-13. doi: 10.1002/1097-0142(20010815)92:4<909::aid-cncr1400>3.0.co;2-h. Cancer. 2001. PMID: 11550165
-
Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.Pediatr Infect Dis J. 2001 Mar;20(3):362-9. doi: 10.1097/00006454-200103000-00036. Pediatr Infect Dis J. 2001. PMID: 11303851 Review.
-
Dimensions of neutropenia in adult cancer patients: expanding conceptualizations beyond the numerical value of the absolute neutrophil count.Cancer Nurs. 2004 Jul-Aug;27(4):275-84; quiz 285-6. doi: 10.1097/00002820-200407000-00003. Cancer Nurs. 2004. PMID: 15292722 Review.
Cited by
-
Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer.Pediatr Blood Cancer. 2015 Feb;62(2):262-268. doi: 10.1002/pbc.25275. Epub 2014 Oct 18. Pediatr Blood Cancer. 2015. PMID: 25327666 Free PMC article.
-
Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study.Br J Cancer. 2017 Jul 11;117(2):171-178. doi: 10.1038/bjc.2017.154. Epub 2017 Jun 13. Br J Cancer. 2017. PMID: 28609435 Free PMC article.
-
Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia.PLoS One. 2012;7(5):e38300. doi: 10.1371/journal.pone.0038300. Epub 2012 May 31. PLoS One. 2012. PMID: 22693615 Free PMC article.
-
Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia.BMC Pediatr. 2005 May 18;5(1):10. doi: 10.1186/1471-2431-5-10. BMC Pediatr. 2005. PMID: 15904510 Free PMC article.
-
Updated review of blood culture contamination.Clin Microbiol Rev. 2006 Oct;19(4):788-802. doi: 10.1128/CMR.00062-05. Clin Microbiol Rev. 2006. PMID: 17041144 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical